CompletedNot Applicable

Evaluation of Implementation of the Phoenix PrEP (Pre-Exposure Prophylaxis) Access Project for Youth Aged 13-24

United States42 participantsStarted 2018-06-01

Plain-language summary

This study will evaluate the implementation of a PrEP program for youth aged 13-24 in Phoenix, AZ. Numbers of youth who initiate PrEP, how long they continue with PrEP, and the barriers for youth who are trying to initiate and continue taking PrEP will be examined.

Who can participate

Age range13 Years – 24 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria * sexually active youth aged 13 through 24, * at risk for contracting HIV, * Negative for HIV as indicated by Negative Elisa and Western Blot (WB) or Negative 4th Generation test, * weight greater than 35kg, * offered PrEP to reduce the risk of contracting HIV. Exclusion Criteria * Unknown or Positive HIV status, * Renal Impairment as indicated by elevated BUN or Creatinine, abnormal urinalysis, * Active infection with Hepatitis B Virus, * Taking other medications containing Emtricitabine, Tenofovir or tenofovir alafenamide(TAF) such as Atripla, Complera, Emtriva, Genvoya, Odefsey, Stribild, and Viread taking drugs containing lamivudine, * taking Hepsera, * clinical symptoms consistent with acute viral infection within the past month.

What they're measuring

PrEP Uptake

Timeframe: 3 years

Trial details

NCT IDNCT03637322

SponsorPhoenix Children's Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-31

View on ClinicalTrials.gov More Unsafe Sex trials